The information on this website is intended for healthcare
professionals only and is provided for the purpose of scientific exchange.
The website is not country specific and may therefore contain
information that is not applicable in your country, thus you may find
information concerning study drugs or therapeutic uses that have not
been approved by drug regulatory agencies. This website is not
intended to promote in any way, any use, either approved, or
unapproved, of a Novo Nordisk product or of any other product or serve
as basis for any treatment decision or action. Please always refer to
Summary of Product Characteristics (product label) as approved by
regulatory authorities in your country or contact Novo Nordisk for
Furthermore, the site is not intended to replace the advice of a
healthcare professional and should not be construed as providing
advice or making a recommendation. Only a physician can determine
whether a specific product is correct for a particular patient. Novo
Nordisk accepts no liability for the accuracy, completeness or use of
this information, and disclaims any liability to update the
information contained on this site.
By accessing this website you accept this legal notice and expressly
confirm your status as a healthcare professional.
ADA 2021 June 25 - 29
Treatment With Once-weekly Semaglutide 2.4 Mg Improves Cardiometabolic Risk Factors In Adults With Overweight/Obesity And Type 2 Diabetes: STEP 2 Post-hoc Analysis
Robert F Kushner1; Melanie Davies2; John E Deanfield3; W Timothy Garvey4; Ole Kleist Jeppesen5; Usman Khalid5; Mikhail Kosiborod6; Peter Norkjaer Laursen5; Domenica M Rubino7; Subodh Verma8;
1 Division of Endocrinology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 2 Diabetes Research Centre, Department of Health Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Leicester, UK; 3 Institute of Cardiovascular Science, University College London, London, UK; 4 Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, USA; 5 Novo Nordisk A/S, Soborg, Denmark; 6 Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute and University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA; 7 Washington Center for Weight Management and Research, Arlington, VA, USA; 8 Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael’s Hospital, Unity Health Toronto, Toronto, ON, Canada;